Your reproductive system does not run on autopilot. It depends on a precisely timed signal from your brain, and LH (luteinizing hormone) is that signal. When LH is too high, too low, or mistimed, the downstream effects ripple through fertility, hormone balance, bone density, and even long-term survival. Knowing your LH level tells you whether the communication line between your brain and your reproductive organs is intact.
LH is not part of any standard lab panel. If you have never specifically requested it, you have never had it measured. That means problems with this signal, from subtle shifts that quietly erode fertility to dramatic surges that indicate ovarian or testicular failure, can go undetected for years.
LH is a signaling protein made by specialized cells in the pituitary gland at the base of your brain. It is released in pulses, roughly every 60 to 90 minutes, in response to another hormone called GnRH (gonadotropin-releasing hormone) from the hypothalamus. This pulsatile pattern is not a quirk of biology. It is essential. If GnRH were released continuously instead of in pulses, LH production would actually shut down.
In women, LH has two primary jobs: it helps regulate the menstrual cycle during the first half, then triggers ovulation through a dramatic midcycle surge. After ovulation, LH supports the production of progesterone from the ovary to sustain a potential pregnancy. In men, LH stimulates the testosterone-producing cells (called Leydig cells) in the testes, which in turn drives sperm production. In children, LH levels remain very low until puberty approaches, when rising levels signal the beginning of sexual maturation.
When LH is elevated, your pituitary is working harder than usual, almost always because the signal it expects back from your gonads is weak. Think of it as your brain turning up the volume because the response is too quiet. In women, this pattern points to primary ovarian insufficiency (the ovaries are failing or have stopped functioning), which includes natural menopause, premature ovarian failure, or genetic conditions like Turner syndrome. In polycystic ovary syndrome (PCOS), LH is often disproportionately high relative to FSH, reflecting an abnormal pulse frequency from the hypothalamus.
In men, elevated LH with low testosterone signals primary testicular failure, which can result from chemotherapy, radiation, infection, or genetic conditions like Klinefelter syndrome. In children, elevated LH and FSH before the expected age of puberty raises concern for precocious puberty, potentially driven by central nervous system disorders.
Low LH tells a different story. Here, the problem is upstream: the brain is not sending the signal. In women, this pattern is the hallmark of functional hypothalamic amenorrhea, where chronic stress, undereating, or excessive exercise suppresses GnRH pulses and shuts down the reproductive axis. In men, low LH with low testosterone points to secondary hypogonadism, a problem at the pituitary or hypothalamus rather than the testes. In either sex, pituitary tumors, head injuries, or infiltrative diseases can damage the cells that produce LH.
Both high and low LH impair fertility, but through different mechanisms. In women with PCOS, chronically elevated LH is associated with both difficulty conceiving and increased miscarriage risk. In functional hypothalamic amenorrhea, suppressed LH pulse frequency leads to absent ovulation entirely. In men, either primary or secondary hypogonadism disrupts sperm production, though the treatment approach differs dramatically depending on whether LH itself is high or low.
This distinction matters for anyone trying to conceive. Exogenous testosterone therapy, for example, suppresses LH and makes a man less fertile, not more. Understanding where the breakdown is occurring, at the testes or at the brain, determines whether the right treatment is replacement hormones or medications that stimulate the body's own production.
In men, elevated LH appears to be more than a marker of reproductive dysfunction. It may signal broader health deterioration. A study of 5,350 Danish men followed for up to 30 years found that men in the highest LH quartile had about a 32% higher risk of dying from any cause compared to men in the lowest quartile. The same group had roughly 42% higher cancer mortality, independent of smoking. These findings held after adjusting for standard risk factors.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| 5,350 Danish men followed up to 30 years | Highest vs. lowest LH quartile | About 32% higher all-cause mortality and 42% higher cancer mortality |
| 3,637 Australian men aged 70 to 88, followed 5.1 years | Each standard-deviation increase in LH | About 15% higher risk of ischemic heart disease (reduced blood flow to the heart) events before adjustment, 8% after |
| 255,830 participant-years across nine studies (meta-analysis) | LH above vs. below 10 IU/L | Higher all-cause mortality after adjusting for cardiovascular risk factors |
Sources: Holmboe et al. (2015), Hyde et al. (2011), Yeap et al. (2024).
What this means for you: elevated LH in men likely reflects compensated testicular dysfunction, where the testes are struggling to produce adequate testosterone and the pituitary is compensating by ramping up LH. This subclinical failure appears to track with overall health decline rather than being an isolated hormonal issue.
In postmenopausal women, the relationship between LH and metabolic health is more nuanced. A study of 3,831 women aged 35 to 60 found that higher LH was associated with about 18.5% lower odds of metabolic syndrome (a cluster of conditions including high blood sugar, excess abdominal fat, and abnormal cholesterol). A separate 5-year study of 114 postmenopausal women found that lower LH was associated with roughly double the risk of developing impaired fasting glucose and insulin resistance.
These findings suggest that in postmenopausal women, higher LH may be a marker of better metabolic health rather than a warning sign. This is the opposite pattern from men, where higher LH signals trouble. The context matters enormously when interpreting your number.
LH reference ranges depend heavily on your sex, age, and, for premenopausal women, where you are in your menstrual cycle. A number that is perfectly normal in one context could be alarmingly high or low in another. Lab-to-lab variation is also significant: a U.S. survey of 117 laboratories found that upper reference limits for LH in men ranged from 4.9 to 86.5 IU/L, reflecting differences in assay methodology and how each lab defines its reference population.
| Population | Typical Range (mIU/mL) | Context |
|---|---|---|
| Men (reproductive age) | 1.6 to 10.0 | Multicenter study using standard laboratory methods |
| Women (follicular phase) | ~1.2 (mean) | Early-to-mid cycle, before ovulation |
| Women (midcycle surge) | ~10.2 (mean) | The ovulation-triggering peak |
| Women (luteal phase) | ~1.0 (mean) | After ovulation |
| Postmenopausal women | 5.8 to 32.0 | Higher end reflects normal postmenopausal elevation |
These ranges are drawn from published research using different assay methods. Your lab may report slightly different cutpoints. The most meaningful comparison is always your own results over time, measured at the same lab and collected under the same conditions.
LH is one of the most variable hormones you can measure. The within-person variability is approximately 26 to 28%, meaning your level can fluctuate by a quarter or more from one draw to the next even when nothing has changed about your health. This is the single most important fact to keep in mind when interpreting a result.
Because LH is released in pulses every 60 to 90 minutes, a single blood draw captures whatever point in the pulse cycle your body happened to be at that moment. You might catch a peak, a trough, or something in between. Morning values tend to run about 18% higher than the daily average, so the time of your draw matters.
Several situations can make a reading unreliable without reflecting a true hormonal problem:
A single LH measurement is a snapshot taken during a pulse. It is not a reliable basis for clinical decisions. Research shows that a single value has a 95% confidence interval of plus or minus 50 to 90%, meaning your true average could be nearly double or half the number on the report. Sampling over six hours narrows that confidence interval to plus or minus 12%, but that is impractical outside a research setting.
The practical solution is serial testing. Two to three measurements, ideally drawn on separate mornings under the same conditions (fasting, 7 to 10 AM, same lab), give you a much more reliable picture than any single draw. If you are making changes, whether starting a medication, adjusting your diet, or modifying exercise intensity, retest in 3 to 6 months to see whether the trend is moving in the right direction. After that, annual monitoring is reasonable for most people tracking reproductive health.
For men evaluating possible hypogonadism, pooled samples (three draws taken 20 minutes apart, combined into one tube) can smooth out the pulse-to-pulse variability in a single visit. For women, consistency in cycle timing is more important than pooling: always draw at the same cycle day, ideally in the early follicular phase (days 2 to 5), unless you are specifically trying to detect the midcycle surge.
Evidence-backed interventions that affect your LH level
LH is best interpreted alongside these tests.